Kura Oncology (NASDAQ: KURA) announced that its Compensation Committee granted inducement awards to 16 new employees on May 1, 2025. The awards consist of nonstatutory stock options to purchase 433,950 shares of common stock under the Company's 2023 Inducement Option Plan. The stock options have an exercise price of $6.49 per share, matching the company's closing price on May 1, 2025. The options will vest over four years, with 25% vesting after one year and the remaining balance vesting monthly over 36 months, contingent on continued employment. These grants were approved as inducement material for employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Kura Oncology (NASDAQ: KURA) ha annunciato che il suo Comitato per la Remunerazione ha assegnato premi di incentivo a 16 nuovi dipendenti il 1° maggio 2025. I premi consistono in opzioni su azioni non statutarie per l'acquisto di 433.950 azioni ordinarie nell'ambito del Piano di Opzioni di Incentivazione 2023 della Società. Le opzioni hanno un prezzo di esercizio di 6,49$ per azione, pari al prezzo di chiusura della società del 1° maggio 2025. Le opzioni matureranno in un periodo di quattro anni, con il 25% che matura dopo un anno e il restante che matura mensilmente nei successivi 36 mesi, a condizione che il rapporto di lavoro continui. Questi premi sono stati approvati come incentivi per l'assunzione in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Kura Oncology (NASDAQ: KURA) anunció que su Comité de Compensación otorgó premios por incentivo a 16 nuevos empleados el 1 de mayo de 2025. Los premios consisten en opciones sobre acciones no estatutarias para comprar 433,950 acciones comunes bajo el Plan de Opciones por Incentivo 2023 de la Compañía. Las opciones tienen un precio de ejercicio de $6.49 por acción, igualando el precio de cierre de la compañía el 1 de mayo de 2025. Las opciones se consolidarán durante cuatro años, con un 25% consolidado tras un año y el saldo restante consolidado mensualmente durante 36 meses, condicionado a la continuidad del empleo. Estas concesiones fueron aprobadas como incentivos para la contratación conforme a la Regla de Cotización Nasdaq 5635(c)(4).
Kura Oncology (NASDAQ: KURA)는 2025년 5월 1일 보상 위원회가 16명의 신입 직원에게 유인 보상을 부여했다고 발표했습니다. 이 보상은 회사의 2023년 유인 옵션 계획에 따라 433,950주의 보통주를 구매할 수 있는 비법정 주식 옵션으로 구성됩니다. 주식 옵션의 행사가격은 2025년 5월 1일 회사 종가인 주당 $6.49입니다. 옵션은 4년에 걸쳐 베스팅되며, 1년 후 25%가 베스팅되고 나머지는 36개월 동안 매월 베스팅되며, 계속 고용 조건에 따라 달라집니다. 이 부여는 Nasdaq 상장 규칙 5635(c)(4)에 따라 고용 유인 자료로 승인되었습니다.
Kura Oncology (NASDAQ : KURA) a annoncé que son comité de rémunération a accordé des primes d'incitation à 16 nouveaux employés le 1er mai 2025. Les primes consistent en des options d'achat d'actions non statutaires portant sur 433 950 actions ordinaires dans le cadre du Plan d'options d'incitation 2023 de la Société. Le prix d'exercice des options est de 6,49 $ par action, correspondant au cours de clôture de la société au 1er mai 2025. Les options seront acquises sur une période de quatre ans, avec 25 % acquis après un an et le solde restant acquis mensuellement sur 36 mois, sous condition de maintien de l'emploi. Ces attributions ont été approuvées en tant qu'incitations à l'emploi conformément à la règle de cotation Nasdaq 5635(c)(4).
Kura Oncology (NASDAQ: KURA) gab bekannt, dass sein Vergütungsausschuss am 1. Mai 2025 Anreizprämien an 16 neue Mitarbeiter vergeben hat. Die Prämien bestehen aus nichtstatutarischen Aktienoptionen zum Kauf von 433.950 Aktien des Stammkapitals gemäß dem Inducement-Optionsplan 2023 des Unternehmens. Der Ausübungspreis der Optionen beträgt 6,49 $ pro Aktie und entspricht dem Schlusskurs des Unternehmens am 1. Mai 2025. Die Optionen werden über vier Jahre unverfallbar, wobei 25 % nach einem Jahr und der verbleibende Anteil monatlich über 36 Monate unverfallbar werden, vorausgesetzt, die Beschäftigung besteht fort. Diese Zuteilungen wurden als Anreize für die Beschäftigung gemäß der Nasdaq-Listing-Regel 5635(c)(4) genehmigt.
Positive
None.
Negative
None.
SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on May 1, 2025, the Compensation Committee of the Company’s Board of Directors (the “Compensation Committee”) granted inducement awards consisting of nonstatutory stock options to purchase 433,950 shares of common stock to sixteen (16) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price equal to $6.49 per share, the Company’s closing sales price on May 1, 2025, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company’s 2023 Inducement Option Plan, as amended, and the terms and conditions of an applicable stock option agreement covering the grant.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of relapsed/refractory (“R/R”) NPM1-mutant acute myeloid leukemia (“AML”). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, and in the second quarter of 2025, the companies announced submission of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-mutant AML. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at https://kuraoncology.com/ and follow us on X and LinkedIn.
What type of stock options did KURA grant to its new employees?
KURA granted nonstatutory stock options to purchase 433,950 shares of common stock with an exercise price of $6.49 per share under the 2023 Inducement Option Plan.
How many new employees received stock options from Kura Oncology in May 2025?
Kura Oncology granted stock options to sixteen (16) new employees.
What is the vesting schedule for KURA's May 2025 employee stock options?
The options vest over 4 years, with 25% vesting after one year and the remaining balance vesting monthly over 36 months, subject to continued employment.
What was the exercise price for KURA's May 2025 inducement stock options?
The exercise price was $6.49 per share, which matched Kura Oncology's closing sales price on May 1, 2025.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
